Compare Charles Schwab Corporation Common Stock (SCHW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs TransMedics Group Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $109.34 (market cap $186.25B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 60.1× TransMedics Group Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SCHW | TMDX | |
|---|---|---|
Market Cap | $186.25B | $3.10B |
Sector | Financials | Technology |
52-Week High | $108.02 | $150.42 |
52-Week Low | $85.35 | $61.99 |
Dividend Yield | 1.19% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $109.28, up 1.19% today, near its all-time high of $109.05 (Zacks Investment Research, 2026-08-07). The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue grew to $23.92 billion in 2025, with net income margin expanding to 37%, while analyst consensus is bullish with a $122.33 price target. Recent news highlights insider selling and ongoing litigation, but institutional acquisitions signal confidence.
Outlook remains positive driven by earnings growth and market share gains, but risks include regulatory scrutiny from lawsuits (Business Wire, 2026-08-10) and interest rate sensitivity. The stock offers upside to consensus targets, though overbought conditions suggest potential near-term volatility. Investors should weigh robust fundamentals against macroeconomic and legal headwinds.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
